Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...
1. Compared to placebo and azacytidine, the combination of ivosidenib and azacitidine demonstrated significant clinical benefit for IDH1-mutated acute myeloid ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.